TCRT — ALAUNOS THERAPEUTICS INC (Healthcare >> Biotechnology)
TCRT FAQ
What is TCRT's ROE?
ALAUNOS THERAPEUTICS INC reports a Return on Equity (ROE) of -319.02%.
What is TCRT's dividend yield?
ALAUNOS THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TCRT's Deepscope Quality Score?
Deepscope rates TCRT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TCRT?
Deepscope's AI Timing Score for TCRT is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TCRT belong to?
ALAUNOS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.99
Price
-0.02
(-1.01%)
Day Change
|
|
|---|
TCRT, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.99 |
| PBV / Sector |
4.10 / 4.71
|
| Earning Per Share | -1.55 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.05 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:50 |
| Symbol | TCRT |
| Name | ALAUNOS THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5.28 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
Phone: 346 355 4099
Website: https://www.alaunos.com
Sector: Healthcare >> Biotechnology
Description: Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google